Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorWood, Mariaen_US
dc.date.accessioned2012-06-07T05:36:50Z
dc.date.issued1997en_US
dc.identifier.citationLearning from Prozac: A Case Study on Reforming the FDA Drug Approval Process (1997 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8846814
dc.description.abstractThe law, focused as it is on making final determinations and settling issues one way or another, continually lags behind science, which concentrates on an evolving understanding of various phenomena through constant enhancement of current understandings of existing realities. Thus, a drug approval process, which obviously deals with scientific issues of drug development, cannot always keep pace with scientific understandings of drug development. The law is flexible and capable of accommodating new understandings, though; therefore, consideration of the scientific issues involved in drug development and approval is appropriate and ought to be undertaken as much as possible in order to develop legal answers that are as accurate as they can be at any given time.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectprozacen
dc.subjectregulatory reformen
dc.subjectprescription drug licensureen
dc.subjecthuman drugsen
dc.subjectFDA approval processen
dc.titleLearning from Prozac: A Case Study on Reforming the FDA Drug Approval Processen
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-06-07T05:36:50Z
dash.authorsorderedfalse


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record